Immunisation of C57BL/6 mice with hamster polyomavirus VP1-derived chimeric virus-like particles (VLPs) displaying murine prion protein residues 128–164 (construct K9) significantly prolonged mean survival after intraperitoneal RML scrapie challenge (240 vs 202 days), yet only weak PrP-specific antibodies were detectable — and only by Western blot of pooled sera — while carrier-only VP1/2 VLPs produced a small, non-significant 12-day delay. The protective mechanism therefore remains unattributed: antibody-mediated interference with the conversion of cellular prion protein (PrPC) into the infectious isoform (PrPSc), a T-cell-mediated effect, or non-specific immunostimulation by the VLP carrier itself. Closely coupled, also unresolved, are the construct-design questions the source paper raised explicitly: the influence of the glycine–serine–serine–glycine (GSSG) linker and VP1 insertion site (K9 vs K1, which differ in efficacy despite carrying the same peptide), and the role of PrP epitope density on the VLP surface.

Background

Prion diseases (transmissible spongiform encephalopathies, TSEs), such as scrapie in sheep, bovine spongiform encephalopathy in cattle, and Creutzfeldt–Jakob disease in humans, are fatal neurodegenerative disorders driven by the conformational conversion of the normal, mainly alpha-helical cellular prion protein (PrPC) into the beta-sheet-rich, aggregation-prone infectious isoform PrPSc, which templates further conversion of PrPC in a self-propagating cycle. No approved therapy exists. Active immunisation is an attractive prophylactic strategy but is hampered by self-tolerance: because PrPC is a host protein, the mammalian immune system responds only weakly to it. Numerous attempts to break this tolerance have used PrP peptides or proteins coupled to carriers (e.g. keyhole limpet haemocyanin), recombinant dimeric PrP with adjuvants, xenogeneic PrP delivered by viral vectors, and passive transfer of monoclonal antibodies; as summarised in the source paper's discussion, antibodies directed at the PrP region around residues 144–159 have shown some of the strongest effects, with passive transfer reportedly prolonging incubation by hundreds of days in mouse scrapie, presumably by sterically blocking or clearing PrPC so that it is unavailable as substrate for conversion into PrPSc. A general lesson from this literature is that protection in murine scrapie models is usually relative — a prolongation of incubation time — rather than sterilising immunity.

One way to present PrP sequences to the immune system in a highly repetitive, immunogenic format is on virus-like particles (VLPs): non-infectious, self-assembling capsid structures that display foreign peptides at defined surface positions without requiring adjuvants. The platform at issue uses the major capsid protein VP1 (with VP2) of hamster polyomavirus (HaPyV), expressed in yeast, which tolerates insertion of foreign segments up to roughly 120 amino acids at several surface-exposed loops. In chimeric VLPs the foreign peptide is inserted directly into VP1 (at insertion site #1, residues 80–89, or site #4, residues 288–295, the latter with a flexible glycine–serine–serine–glycine (GSSG) linker flanking the insert); in pseudotype VLPs an unmodified VP1 particle additionally carries a VP2 fusion protein, which displays the foreign peptide at lower density on the particle surface.

Eiden, Gedvilaitė, Leidel, Ulrich and Groschup (Viruses 2021) immunised C57BL/6 mice with nine HaPyV-VLP constructs displaying different murine PrP fragments, then challenged the mice intraperitoneally with the RML strain of mouse scrapie. Only construct K9 — chimeric VP1 VLPs carrying the 37-amino-acid PrP fragment P1 (residues 128–164, spanning the first alpha-helix of the globular domain at residues 143–153 and two short beta-strands) at insertion site #1 — significantly prolonged mean survival, from 201.6 ± 4.5 to 240.4 ± 13.6 days (about 18%). The PrP-specific humoral response was weak: antibodies were detected by Western blot only in pooled sera from K9-immunised animals, and not at all by enzyme-linked immunosorbent assay (ELISA) of individual sera. Construct K1, which carries the same peptide P1 but at insertion site #4, showed a similar but statistically non-significant prolongation (+34.6 vs +38.8 days for K9), reflecting high inter-animal variability in that group; the authors attributed the difference in protective potential between K9 and K1 to either the presence/absence of the GSSG linker or the different insertion site. Pseudotype constructs were ineffective, possibly because of the lower PrP epitope density on the VLP surface, and carrier-only VP1/2 VLPs produced a slight (12-day), non-significant increase in survival. The paper proposes to test this density dependence in further experiments with the P1 peptide fused to the VP2 protein of HaPyV. Because VLPs are known to also induce cellular responses, including cytotoxic T lymphocytes (CTLs) and pro-inflammatory cytokine release, the authors could not determine whether the protective effect of K9 was antibody-mediated, T-cell-mediated, or partly a non-specific effect of the VLP carrier itself — a distinction that matters for any rational design of a prion vaccine.

Problem Statement

For the hamster polyomavirus VLP vaccine platform displaying murine PrP peptides in scrapie-infected mice, determine (i) the immune mechanism by which the protective construct K9 — chimeric VP1 VLPs carrying PrP residues 128–164 at insertion site #1 — prolongs survival after intraperitoneal RML challenge, discriminating between antibody-mediated protection (induced anti-PrP auto-antibodies interfering with PrPC-to-PrPSc binding/conversion or depleting cell-surface PrPC), a T-cell-mediated effect (e.g. a VLP-induced cytotoxic T lymphocyte response), and a non-specific contribution of the VLP carrier itself (suggested by the 12-day, non-significant effect of carrier-only VP1/2 VLPs); and (ii) the epitope-display design rules governing efficacy on this platform, namely the influence of the GSSG linker and VP1 insertion site, which differ together between the two constructs compared (K9 at site #1, which lacks the linker, vs K1 at site #4, which carries it, both displaying the same peptide P1) and the role of PrP epitope density on the VLP surface. Within (i), the three mechanisms potentially contribute as relative or combined effects rather than as mutually exclusive alternatives. These two components jointly serve one overarching objective, framed by the source paper's own Conclusions — establishing a PrP-VLP vaccine whose protective mechanism is understood and whose construct design is rational, and thereby determining the potential of such a vaccine for prophylactic or even therapeutic (post-exposure) interventions in currently fatal and incurable prion diseases — rather than an independent mandate to assess that potential.

References

  1. Eiden M, Gedvilaitė A, Leidel F, Ulrich RG, Groschup MH. Vaccination with Prion Peptide-Displaying Polyomavirus-Like Particles Prolongs Incubation Time in Scrapie-Infected Mice. Viruses 2021, 13(5), 811. doi:10.3390/v13050811, https://doi.org/10.3390/v13050811 (open access full text: PMC8147134)
  2. Napper S, Schatzl HM. Vaccines for prion diseases: a realistic goal? Cell and Tissue Research 2023, 392(1), 367–392. doi:10.1007/s00441-023-03749-7, https://doi.org/10.1007/s00441-023-03749-7
  3. Triller G, Garyfallos DA, Papavasiliou FN, Sklaviadis T, Stavropoulos P, Xanthopoulos K. Immunization with Genetically Modified Trypanosomes Provides Protection against Transmissible Spongiform Encephalopathies. International Journal of Molecular Sciences 2022, 23(18), 10629. doi:10.3390/ijms231810629, https://doi.org/10.3390/ijms231810629
  4. Jandrig B, Krause H, Zimmermann W, Vasiliunaite E, Gedvilaitė A, Ulrich RG. Hamster Polyomavirus Research: Past, Present, and Future. Viruses 2021, 13(5), 907. doi:10.3390/v13050907, https://doi.org/10.3390/v13050907
  5. Fang A, Tang X, Fleming M, Tancowny B, Wang X, Wang Y, Daude N, Dorosh L, Fleck SC, Rathod V, Coustou V, Cervantes SA, Duque Velásquez C, Westaway D, Aiken J, McKenzie D, Telling G, Stepanova M, Saupe SJ, Siemer AB, Wille H. A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann–Sträussler–Scheinker disease mutation. Acta Neuropathologica 2026, 151(1). doi:10.1007/s00401-026-03015-4, https://doi.org/10.1007/s00401-026-03015-4 (open access full text: PMC13090231)
  6. Mukherjee A, Biswas S, Roy I. Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases. Acta Pharmacologica Sinica 2025, 46(6), 1511–1538. doi:10.1038/s41401-024-01455-w, https://doi.org/10.1038/s41401-024-01455-w
  7. Elsutohy MM, Abdelaziz D, Dalton CS, Kruger B, Phan S, Cheng YC, Low K, Ahmed-Hassan H, Schätzl HM. PLGA nanoparticles for oral delivery of prion-specific antigen: a novel approach to chronic wasting disease vaccination. Scientific Reports 2025, 16, 1481. doi:10.1038/s41598-025-31381-8, https://doi.org/10.1038/s41598-025-31381-8